Shares of Glenmark Pharmaceuticals struck a fresh high
Advertisement
Advertisement
Glenmark said its US unit has been granted final approval by the United States Food and Drug Administration for Drospirenone and Ethinyl Estradiol Tablets USP, 3mg/0.02 mg, the generic version of Yaz Tablets of Bayer HealthCare Pharmaceuticals Inc.
As a consequence, Glenmark added 50 rupees, or 4.4 percent, to 1209.80 rupees on the National Stock Exchange where 11 lakh shares were traded compared with a 5-day average of 16.6 lakh shares.
Glenmark's market capitalisation has gained 68 percent in the past one year to 33,800 crore rupees as investors preferred the relative predictability of pharma revenues. The stock trades 8 times book value of 146 rupees.
Image credit: Indiatimes
Advertisement
Advertisement
- Should you be worried about the potential side-effects of the Covishield vaccine?
- India T20 World Cup squad: KulCha back on menu, KL Rahul dropped
- Sales of homes priced over ₹4 crore rise 10% in Jan-Mar in top 7 cities: CBRE
- Gold prices fluctuate as geopolitical tensions ease; US Fed meeting, payroll data to affect prices this week
- Best beaches to visit in Goa in 2024